2011

1. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

   Annals of Oncology, Vol. 22, Núm. 12, pp. 2646-2653